What is Third Harmonic Bio?
Third Harmonic Bio is a clinical-stage biopharmaceutical firm headquartered in Cambridge, Massachusetts, dedicated to developing innovative oral therapies for severe allergic and inflammatory conditions. The company's focus on a novel oral delivery mechanism aims to provide a more convenient and effective treatment option for patients suffering from debilitating immune-mediated diseases.
How much funding has Third Harmonic Bio raised?
Third Harmonic Bio has raised a total of $105M across 1 funding round:
Series B
$105M
Series B (2022): $105M with participation from BVF Partners and General Atlantic
Key Investors in Third Harmonic Bio
BVF Partners
BVF Partners is a San Francisco-based private investment partnership that specializes in public biotechnology investments, with a focus on concentrated, long-term holdings in small-cap biotech companies.
General Atlantic
General Atlantic is a global growth equity firm providing capital and strategic support to high-growth companies across various sectors, including life sciences, with a global presence and a focus on accelerating growth.
What's next for Third Harmonic Bio?
With the recent major strategic investment, Third Harmonic Bio is poised to accelerate its clinical development pipeline. The substantial backing suggests a strong investor confidence in the company's therapeutic platform and its potential to address significant unmet medical needs in allergy and inflammation. Future endeavors will likely focus on advancing lead candidates through rigorous clinical trials, expanding the research team, and potentially forging strategic partnerships to broaden market reach and therapeutic applications.
See full Third Harmonic Bio company page
